Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma
Status:
Recruiting
Trial end date:
2025-01-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and best dose of anakinra and to see how well it
works in reducing side effects (toxicity) associated with a CAR-T cell treatment called
axicabtagene ciloleucel in patients with large B-cell lymphoma that has come back (relapsed)
or has not responded to treatment (refractory). Anakinra is a drug typically used to treat
rheumatoid arthritis but may also help in reducing CAR-T cell therapy toxicity. Giving
anakinra in combination with axicabtagene ciloleucel may help control relapsed or refractory
large B-cell lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Cyclophosphamide Fludarabine Interleukin 1 Receptor Antagonist Protein